Sinovac Reports Unaudited First Quarter 2010 Financial Results
leading
financial results for the three-month period ended
First Quarter 2010 Financial Highlights (comparisons to First Quarter 2009)
-- Sales for the first quarter decreased 32% to $4.4 million
-- Operating loss for the first quarter was $865,000, compared to
operating income of $646,000
-- Net loss attributable to shareholders for the first quarter was
$307,000, with loss per diluted share of $0.01
-- Cash and cash equivalents at March 31, 2010 increased to $118.9 million,
reflecting the closing of the common share public offering in February
2010
Business Highlights
-- In April 2010, Sinovac's joint venture, Sinovac Dalian, submitted an
application to China's State Food and Drug Administration (SFDA) to
commence human clinical trials for its mumps vaccine. The proprietary
mumps vaccine developed by Sinovac Dalian represents not only the first
live attenuated vaccine for which Sinovac Dalian has filed a clinical
trial application, but also the first candidate from the joint
venture's pipeline for which a clinical trial application has been
submitted to and accepted by the SFDA since the formation of the joint
venture in January 2010.
-- In May 2010, Sinovac Biotech, through its wholly owned subsidiary
Sinovac Biotech (Hong Kong) Ltd, made an initial cash contribution of
60 million RMB, or approximately $8.8 million, to Sinovac Dalian, the
Company's 30%-owned joint venture that was established in January 2010.
Mr.
indicated in early April, the demand for the vaccinations in the private pay
market across
reports that the SFDA subsequently determined to be unfounded. As a leading
supplier of hepatitis A and seasonal influenza vaccines to the private pay and
public markets, our first quarter 2010 sales were impacted by the reduced
industry demand. Our domestic sales and marketing strategy is being augmented
to reflect the current landscape. We are expanding our geographic reach by
focusing on the rural markets and are providing physician education programs
to drive growth in the private pay market. We continue to collaborate with our
local distribution partners to obtain requisite approvals in targeted
international markets, including
Mr. Yin continued, “Given our long term expectations for increasing demand
for our vaccines products, initiatives are underway to bring on additional
capacity that will enable us to both expand production of our commercialized
vaccines and commence production of our pipeline vaccines in a condensed
timeframe upon receipt of production licenses. At our 300,000 square foot
production facility in the Changping District,
completion of the build-out of two new production lines in the second half of
2010. These new production lines will have a combined annual capacity of
approximately 40 million doses and will be utilized to manufacture our
currently marketed flu vaccines and our pipeline EV71 vaccine. At Sinovac
Dalian’s 200,000 square foot production facility, two vaccine production lines
are operational — one for animal cell cultured vaccines and one for live
attenuated vaccines.”
Mr. Yin concluded, “Advancing our research and development pipeline of
proprietary vaccines continues to be a critical component of our growth
strategy. Through our Sinovac Dalian joint venture, we have already submitted
a clinical trial application for the mumps vaccine to the SFDA, exemplifying
our commitment to building our pipeline and expanding our portfolio of
commercialized vaccines. During the quarter, we further strengthened our R&D
team, adding specialists both at our headquarters and at our joint venture.
Through our in-house development and in collaboration with domestic and
international partners, we are advancing our robust pre-clinical development
pipeline that encompasses pneumococcal conjugated vaccine, rabies vaccine, HIB
vaccine, meningitis vaccine, chickenpox (varicella) vaccine, and rubella
vaccine.”
Financial Review for Three Months Ended
First quarter 2010 results included the consolidation of the financial
results from the 30%-owned joint venture, Sinovac Dalian, following its
formation in
Sales for the first quarter of 2010 were
million
2010 were attributable to the lower demand in the private pay market based on
concerns over product safety given the recent media reports linking the
improper storage of vaccines by a distributor to a few cases of serious
adverse events in
related to Sinovac and its products, impacted the entire vaccine industry in
investigation.
Sinovac's sales breakdown by product was as follows.
Three months ended March 31
2010 2009
Sales
Healive $2,539,634 $4,902,315
Bilive 541,059 1,196,177
Anflu 31,796 467,607
Panflu.1 (H1N1) 1,331,410 --
Total $4,443,899 $6,566,099
Sales of the Panflu.1 (H1N1) vaccine represented 29.96% of total sales for
the three months ended
Chinese government in accordance with the government purchase program.
Gross profit for the first quarter of 2010 was
margin of 80%, compared to
period of 2009. The gross margin for the first quarter of 2010 increased due
to the product mix during the current year quarter.
Selling, general and administrative expenses for the first quarter of 2010
were
expenses as a percentage of first quarter 2010 sales were 70%, compared to 54%
during the first quarter of the prior year. The higher SG&A expenses as a
percentage of revenue resulted from the additional G&A expenses associated
with the 30%-owned joint venture, partly offsetting the lower selling costs
associated with the first quarter 2010 revenues.
Net research and development expenses for the first quarter 2010 were
expenses in the first quarter of 2010 were primarily related to the continued
development of EV71 vaccine, pneumococcal conjugated vaccine, rabies vaccines
for human and animals, along with the mumps vaccine, which is currently under
development at Sinovac Dalian.
Depreciation of property, plant and equipment and amortization of license
and permits for the first quarter of 2010 rose to
attributable to depreciation expense at Sinovac Dalian that was included in
the first quarter 2010 consolidated results.
Total operating expenses for the first quarter of 2010 were
compared to
The operating loss for the three months ended
compared to operating income of
The operating loss in the first quarter of 2010 was attributable to the
increased administrative expenses from Sinovac Dalian, reduced sales and
higher R&D expenses.
Net income for the first quarter of 2010 included
financing expenses,
income tax recovery. Net income for the same period of 2009 included
of interest and financing expenses,
first quarter of 2010 was
compared to net income attributable to shareholders of
diluted share, in the same period of 2009.
As of
million
cash and cash equivalents primarily reflects the contribution of approximately
closed in
Recent Developments
Sinovac’s 30%-owned joint venture, Sinovac Dalian, submitted an
application to the SFDA to commence human clinical trials for its mumps
vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents
not only the first live attenuated vaccine for which Sinovac has filed a
clinical trial application, but also the first candidate from the joint
venture’s pipeline for which a clinical trial application has been submitted
to and accepted by the SFDA since the formation of the joint venture in
After receiving regulatory approval from
Foreign Exchange, Sinovac Biotech, through its wholly owned subsidiary Sinovac
Biotech (
or approximately
other party, made an asset contribution, inclusive of its manufacturing
facilities, production lines and land use rights, with an appraised value of
divided 30% and 70% between Sinovac and Dalian Jin Gang Group, respectively.
Pursuant to the agreement executed between Sinovac and Dalian Jin Gang Group,
Sinovac intends to increase its equity shares to 55%, in exchange for a cash
contribution of
2010 Guidance
Sinovac anticipates that the impact of the unfounded
on the vaccine industry will gradually diminish as the SFDA has clarified that
the fatalities were not connected to the vaccines; however it may take some
time for public perceptions of vaccine safety to recover. As such, the Company
has adjusted its total 2010 sales expectations to the range of approximately
of Panflu.1 purchased by the government will be delivered to the local CDC and
the remaining 8.74 million doses of Panflu.1 will be stockpiled by the
government in the Company’s warehouse facility in 2010. The revenue from the
2.15 million H1N1 vaccine doses, which are expected to be delivered this year,
is included in the 2010 sales guidance. The Company expects that the revenue
from the 8.74 million H1N1 vaccine doses will be recognized in 2011, if they
have not been delivered before the shelf life of the vaccine expires.
In 2010, the Company expects to advance the clinical development of its
pipeline products as follows: (i) to commence clinical trials in
enterovirus 71 (EV 71) vaccine and Japanese encephalitis vaccine upon
receiving approval of its clinical trial applications from SFDA; (ii) to file
the clinical trial application with the SFDA for its pneumococcal conjugate
vaccine; and (iii) to commence clinical trials in
under development at Sinovac Dalian upon receiving approval for its clinical
trial application from the SFDA The Company intends to continue executing its
business plan at the Sinovac Dalian and the Changping facilities to increase
production capacity of its commercialized vaccines and prepare for the
commercialization of its pipeline products.
Conference Call Details
The Company will host a conference call on
p.m. EDT
Company’s financial results for the first quarter ended
provide an update on recent corporate developments. To access the conference
call, please dial 1-877-407-4018 (
replay of the call will be available from
1-201-612-7415 (international) and reference the account number 3055 and the
access code 350462. A live audio webcast of the call will also be available
from the Investors section on the corporate web site athttp://www.sinovac.com .
A webcast replay can be accessed on the corporate website beginning
2010
About Sinovac
Sinovac Biotech Ltd. is a
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac’s
commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM)
(pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)).
Sinovac is developing vaccines for enterovirus 71, universal pandemic
influenza, pneumococcal infection, Japanese encephalitis, and human rabies.
Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal rabies vaccines. Its 30%-owned
joint venture, Sinovac Dalian, focuses on the research, development,
manufacturing and commercialization of vaccines, such as rabies, chickenpox,
mumps and rubella vaccines for human use.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac’s beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
For further information, please contact:
Sinovac Biotech Ltd.
Helen G. Yang
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com
SINOVAC BIOTECH LTD.
Incorporated in Antigua and Barbuda
Consolidated Balance Sheets
(Unaudited)
(Expressed in U.S. Dollars)
March 31, December 31,
2010 2009
ASSETS
Current assets
Cash and cash equivalents $118,932,465 $74,953,212
Restricted cash 6,440 64,400
Short-term investments 8,338,088 7,313,149
Accounts receivable - net 22,713,648 24,540,134
Inventories 13,779,138 9,599,118
Prepaid expenses and deposits 802,158 466,346
Due from related party 3,286,046 --
Deferred tax assets 1,133,010 1,375,174
Total current assets 168,990,993 118,311,533
Property, plant and equipment 40,624,385 22,306,688
Deposits for acquisition of assets 8,264,946 --
Long-term inventories 2,642,242 2,642,734
Deferred tax assets 507,363 520,077
Licenses and permits 595,660 695,109
Due from related party 3,286,046 --
$224,911,635 $144,476,141
Total assets
LIABILITIES AND EQUITY
Current liabilities
Loans payable $17,700,151 $17,697,821
Accounts payable and accrued
liabilities 11,163,976 17,784,509
Income tax payable 3,786,171 6,413,734
Deferred revenue 5,153,407 5,386,749
Deferred research grants 1,360,908 1,331,476
Deferred tax liability 1,835,953 1,398,123
Total current liabilities 41,000,566 50,012,412
Deferred government grants 2,581,188 2,646,669
Loans payable 8,264,946 --
Long term payable 407,847 407,794
Deferred revenue 6,943,738 6,942,824
Total long term liabilities 18,197,719 9,997,287
Total liabilities 59,198,285 60,009,699
Commitments and contingencies
EQUITY
Preferred stock -- --
Authorized 50,000,000 shares at par
value of $0.001 each
Issued and outstanding: nil
Common stock 54,097 42,585
Authorized: 100,000,000 shares at
par value of $0.001 each
Issued and outstanding: 54,097,261
(2009- 42,585,261 )
Additional paid in capital 104,493,734 42,533,876
Accumulated other comprehensive
income 4,232,442 4,225,196
Dedicated reserves 9,863,251 9,863,251
Retained earnings 13,685,977 13,993,287
Total stockholders' equity 132,329,501 70,658,195
Non-controlling interests 33,383,849 13,808,247
Total equity 165,713,350 84,466,442
Total liabilities and equity $224,911,635 $144,476,141
SINOVAC BIOTECH LTD.
Incorporated in Antigua and Barbuda
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Three Months Ended March 31, 2010 and 2009
(Unaudited)
(Expressed in U.S. Dollars)
Three months ended
March 31
2010 2009
Sales $4,443,899 $6,566,099
Cost of sales - (exclusive of
depreciation of land-use rights and
amortization of licenses and permits
of $104,793 (2009-$104,633 ) 883,475 1,447,770
Gross profit 3,560,424 5,118,329
Selling, general and administrative
expenses 3,092,248 3,547,623
Research and development expenses -
net of $17,554 (2009 - $58,311) in
government research grants 907,959 759,441
Depreciation of property, plant and
equipment and amortization of
licenses and permits 425,427 164,869
Total operating expenses 4,425,634 4,471,933
Operating income (loss) -865,210 646,396
Interest and financing expenses -124,375 -126,200
Interest income and other income
(expenses) -492,592 93,131
Income (loss) before income taxes and
non-controlling interests -1,482,177 613,327
Income tax recovery (expenses) 269,479 -481,768
Consolidated net income (loss) for
the period -1,212,698 131,559
Loss (income) attributable to non -
controlling interests 905,388 -106,880
Net income (loss) attributable to
stockholders $-307,310 $24,679
$-1,212,698 $131,559
Net income (loss)
Other comprehensive income
Foreign currency translation
adjustment 8,723 64,899
Total comprehensive income (loss) -1,203,975 196,458
Comprehensive loss (income)
attributable to non-controlling
interests 903,911 -123,043
Comprehensive income (loss)
attributable to stockholders $-300,064 $73,415
Earnings (loss) per share - basic
and diluted $-0.01 $0
Weighted average number of shares of
common stock outstanding
- Basic and Diluted 49,873,422 42,890,695
SINOVAC BIOTECH LTD.
Incorporated in Antigua and Barbuda
Consolidated Statements of Cash Flows
Three Months Ended March 31, 2010 and 2009
(Unaudited)
(Expressed in U.S. Dollars)
Three months ended
March 31
2010 2009
Cash flows used in operating
activities
Net income (loss) for the period $(1,212,698) $131,559
Adjustments to reconcile net income
to net cash used in operating
activities:
- deferred income taxes 692,520 157,394
- stock-based compensation 103,664 66,503
- inventory provision 16,206 --
- provision for doubtful accounts -- 868,938
- write-off equipment and loss on
disposal 687,095 (9,783)
- research and development
expenditures qualified for
government grant (17,554) (58,311)
- depreciation of property, plant
and equipment and amortization of
licenses and permits 891,007 483,670
- deferred government grant
recognized in income (65,830) (51,316)
- accounts receivable 1,829,731 (2,462,999)
- inventories (3,771,749) (2,331,763)
- income tax payable (2,628,408) (885,252)
- prepaid expenses and deposits (335,770) 30,904
- long term payable, deferred
revenue and advances from customers (234,054) --
- accounts payable and accrued
liabilities (6,100,581) (2,771,775)
Net cash used in operating activities (10,146,421) (6,832,231)
Cash flows from (used in) financing
activities
- Loan proceeds 8,265,031 --
- Proceeds from issuance of common
stock net of share issuance costs 61,867,706 --
- Repurchase of common shares -- (319,643)
- Loan to non-controlling
shareholder of Sinovac Beijing (6,572,159) (1,460,600)
- Government grant received 46,811 --
Net cash provided by (used in)
financing activities 63,607,389 (1,780,243)
Cash flows used in investing
activities
- Restricted cash 57,961 --
- Proceeds from disposal of
equipment 189,876 --
- Proceeds from redemption of short -
term investments 7,314,187 --
- Purchase of short-term investments (8,338,173) --
- Prepaid for acquisition of new
facility (8,265,031) --
- Acquisition of property, plant and
equipment (448,165) (1,011,492)
Net cash used in investing activities (9,489,345) (1,011,492)
Exchange gain on cash and cash
equivalents 7,630 38,743
Increase in cash and cash equivalents 43,979,253 (9,585,223)
Cash and cash equivalents, beginning
of period 74,953,212 32,894,102
Cash and cash equivalents, end of
period $118,932,465 $23,308,879
Supplemental disclosure of cash flow
information:
Cash paid for interest $268,279 $123,402
Cash paid for income taxes $1,653,353 $1,209,626
Supplemental schedule of non-cash
activities:
Acquisition of property, plant and
equipment included in
Accounts payable and accrued
liabilities $798,541 $1,092,789
SOURCE Sinovac Biotech Ltd.